×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AUTL – autolus therapeutics plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AUTL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
05:31 pm
autl
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
Medium
Report
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
11/19
05:31 pm
autl
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
Medium
Report
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
11/18
08:06 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $7.60 price target on the stock, up previously from $7.00.
Medium
Report
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $7.60 price target on the stock, up previously from $7.00.
11/15
08:27 am
autl
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023) [Yahoo! Finance]
11/15
08:04 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at Redburn Atlantic from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.
Medium
Report
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at Redburn Atlantic from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.
11/14
05:02 am
autl
BioNTech signs agreement to acquire Biotheus [Yahoo! Finance]
Medium
Report
BioNTech signs agreement to acquire Biotheus [Yahoo! Finance]
11/13
02:26 am
autl
Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Low
Report
Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
11/12
07:00 am
autl
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Medium
Report
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
07:00 am
autl
autolus therapeutics plc - american depositary shares
MISS
Report
-9.8%
autolus therapeutics plc - american depositary shares
8/8/2024
07:00 am
autl
autolus therapeutics plc - american depositary shares
MISS
Report
-9.0%
autolus therapeutics plc - american depositary shares
5/17/2024
07:00 am
autl
autolus therapeutics plc - american depositary shares
MISS
Report
4.8%
autolus therapeutics plc - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:33 pm
autl
Form SC 13G/A Autolus Therapeutics Filed by: Paradigm Biocapital Advisors LP
Low
Report
Form SC 13G/A Autolus Therapeutics Filed by: Paradigm Biocapital Advisors LP
11/14
01:45 pm
autl
Form SC 13G/A Autolus Therapeutics Filed by: Syncona Portfolio Ltd
Low
Report
Form SC 13G/A Autolus Therapeutics Filed by: Syncona Portfolio Ltd
11/14
09:12 am
autl
Form SC 13G/A Autolus Therapeutics Filed by: Deep Track Capital, LP
High
Report
Form SC 13G/A Autolus Therapeutics Filed by: Deep Track Capital, LP
11/12
04:28 pm
autl
Form 10-Q Autolus Therapeutics For: Sep 30
Medium
Report
Form 10-Q Autolus Therapeutics For: Sep 30
11/12
09:51 am
autl
Form SC 13G Autolus Therapeutics Filed by: FMR LLC
Medium
Report
Form SC 13G Autolus Therapeutics Filed by: FMR LLC
11/12
09:25 am
autl
Form 8-K Autolus Therapeutics For: Nov 12
Medium
Report
Form 8-K Autolus Therapeutics For: Nov 12
11/12
09:22 am
autl
Form 8-K Autolus Therapeutics For: Nov 08
Medium
Report
Form 8-K Autolus Therapeutics For: Nov 08
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/25
Visiongain Report Looks at Opportunities Within the $23bn Cell Therapy Technologies Market
18.8%
3/3 Autolus Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Progress 6.7%
5/14 Q1/2019 3/31/2019 EPS -0.690 ZacksConsensus -0.580 ActVsEst (0.110) - Miss 6.5%
12/7 Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers 6.4%
11/5 Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting 6.0%
4/14 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) - Global Market Insights and Forecast to 2030 - ResearchAndMarkets.com 5.7%
3/19 Autolus Therapeutics (AUTL) Investor Presentation - Slideshow [Seeking Alpha] 5.4%
2/13 The Alliance for Regenerative Medicine Releases Agenda for 2020 Cell & Gene Meeting on the Mediterranean 4.9%
4/21 Autolus Therapeutics Ltd - (NASDAQ: AUTL) is now covered by analysts at Mizuho. They set a "buy" rating on the stock. 4.7%
10/9 3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting [The Motley Fool] 4.6%
3/3 Autolus Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Progress 6.7%
5/14 Q1/2019 3/31/2019 EPS -0.690 ZacksConsensus -0.580 ActVsEst (0.110) - Miss 6.5%
12/7 Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers 6.4%
11/5 Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting 6.0%
4/14 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) - Global Market Insights and Forecast to 2030 - ResearchAndMarkets.com 5.7%
3/19 Autolus Therapeutics (AUTL) Investor Presentation - Slideshow [Seeking Alpha] 5.4%
2/13 The Alliance for Regenerative Medicine Releases Agenda for 2020 Cell & Gene Meeting on the Mediterranean 4.9%
4/21 Autolus Therapeutics Ltd - (NASDAQ: AUTL) is now covered by analysts at Mizuho. They set a "buy" rating on the stock. 4.7%
10/9 3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting [The Motley Fool] 4.6%
TOP News Decliners
1/22
Autolus Announces Proposed Public Offering in the United States
-14.6%
8/9 Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -13.6%
8/8 Form 6-K Autolus Therapeutics For: Jun 30 -13.0%
8/8 Q2/2019 6/30/2019 EPS -0.650 ZacksConsensus -0.760 ActVsEst 0.110 - Beat -12.1%
3/9 Maryland Tech Council Announces the Finalists for the Industry Awards Celebration -11.0%
5/7 Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14 -8.1%
2/25 Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference -8.1%
9/9 Form SC 13G/A Autolus Therapeutics Filed by: Woodford Patient Capital Trust Plc -7.8%
2/18 Cell Therapy Manufacturing Market Landscape & Opportunity Assessment, 2019-2030 -7.2%
11/12 Autolus Therapeutics Ltd - (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. -6.0%
8/9 Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -13.6%
8/8 Form 6-K Autolus Therapeutics For: Jun 30 -13.0%
8/8 Q2/2019 6/30/2019 EPS -0.650 ZacksConsensus -0.760 ActVsEst 0.110 - Beat -12.1%
3/9 Maryland Tech Council Announces the Finalists for the Industry Awards Celebration -11.0%
5/7 Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14 -8.1%
2/25 Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference -8.1%
9/9 Form SC 13G/A Autolus Therapeutics Filed by: Woodford Patient Capital Trust Plc -7.8%
2/18 Cell Therapy Manufacturing Market Landscape & Opportunity Assessment, 2019-2030 -7.2%
11/12 Autolus Therapeutics Ltd - (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: